VCYT — Veracyte, Inc.

Summary of VCYT Q3 2025 Earnings Call

1. Key Financial Results and Metrics:

• Total revenue for Q3 2025 reached approximately $132 million, reflecting a 14% year-over-year growth.
• Core testing revenue grew by 17% year-over-year, driven by 26% growth in Decipher and 13% growth in Afirma.
• Adjusted EBITDA margin improved to a record 30.1%, up 650 basis points from the prior year, exceeding expectations.
• GAAP net income was $19.1 million, impacted by a $6.7 million loss from the deconsolidation of Veracyte SAS.
• Cash generated from operations totaled $44.8 million, with cash and cash equivalents at $366 million.

2. Strategic Updates and Business Highlights:

• Decipher achieved 26,700 tests in Q3, marking 14 consecutive quarters of over 25% year-over-year volume growth.
• The company is expanding Decipher's clinical utility, particularly in high-risk localized and metastatic prostate cancer patients, supported by new research findings.
• Afirma testing volume increased by 13%, with a successful transition to a new v2 transcriptome workflow expected to enhance patient access to testing.
• Veracyte is advancing its whole genome-based MRD platform, with multiple studies underway across various cancer types, aiming for a proof of concept in muscle invasive bladder cancer (MIBC) by the first half of 2026.
• Prosigna is on track for a launch as an LDT in the U.S. breast cancer market in mid-2026, with ongoing studies supporting its clinical utility.

3. Forward Guidance and Outlook:

• The company raised its 2025 total revenue guidance to $506 million to $510 million from a previous range of $496 million to $504 million.
• Testing revenue guidance was also increased to $484 million to $487 million, reflecting strong Decipher and Afirma performance.
• Adjusted EBITDA margin guidance for the year was raised to exceed 25%, indicating strong profitability and operational efficiency.

4. Bad News, Challenges, or Points of Concern:

• The company noted a decline in biopharmaceutical and other revenue, down to $800,000 from $3.1 million in Q3 2024 due to restructuring and liquidation of Veracyte SAS.
• There is ongoing competitive pressure from emerging digital pathology technologies, which have shown discordance with Decipher results, potentially confusing clinicians.
• The transition to the new Afirma v2 transcriptome may present operational challenges, though early data is promising.

5. Notable Q&A Insights:

• Management emphasized the importance of clinical evidence in supporting Decipher's adoption over emerging technologies, asserting that Decipher remains the gold standard.
• There is a strong overlap between urologists treating prostate cancer and those who will use the MRD assay, with expectations to reach 70% of the total addressable market.
• The company is strategically focused on building its breast cancer sales channel in a measured way, similar to its successful approach with Decipher.
• Future investments will be balanced with maintaining a target adjusted EBITDA margin of approximately 25%.

Overall, Veracyte reported strong financial performance in Q3 2025, driven by growth in its core testing business, while also navigating challenges related to competition and restructuring efforts. The outlook remains positive with raised guidance and strategic initiatives aimed at expanding its market presence.